Catalogue


Self-Administered drug treatments for acute migraine headache [electronic resource] /
contributing authors, Rebecca N. Gray ... [et al.].
imprint
Rockville, MD : Agency for Health Care Policy and Research (US), [1999]
format(s)
Book
Holdings
More Details
added author
imprint
Rockville, MD : Agency for Health Care Policy and Research (US), [1999]
restrictions
Licensed for access by U. of T. users.
general note
"February 1999."
Title from home page caption (viewed Apr. 4, 2011).
abstract
OBJECTIVE: The objective was to identify and summarize evidence from controlled trials on the efficacy and tolerability of self-administered drug treatments for acute migraine headache. SEARCH STRATEGY: A strategy combining the MeSH term "headache" (exploded) and a previously published strategy for identifying randomized controlled trials was used on the January 1966 to December 1996 MEDLINE database. Other computerized bibliographic databases, textbooks, and experts were also utilized. SELECTION CRITERIA: English-language controlled trials involving patients with acute migraine headache in which at least one treatment offered was a self-administered drug treatment were included. DATA COLLECTION AND ANALYSIS: The number of patients obtaining headache relief according to an a priori definition of at least a 50% reduction in pain severity was recorded and used to calculate odds ratios for headache relief Measures of pain severity reported as group means (and standard deviations) were used to calculate standardized mean differences (or effect sizes). Where similar trials provided data, meta-analysis of efficacy measures was performed. The identity and rates of adverse events were recorded and statistically compared. MAIN RESULTS: Placebo-controlled trials support the efficacy of a number of self-administered treatments for acute migraine, including non-steroidal anti-inflammatory drugs (NSAIDs), dihydroergotamine (DHE) nasal spray, sumatriptan (in subcutaneous, oral, and intranasal formulations), and opiate analgesics (codeine and butorphanol). Evidence supporting the efficacy of ergot alkaloids and isometheptene compounds is weaker. Comparisons among alternative drug treatments are few in number and mostly inconclusive. Controlled trials of antinauseants or caffeine used in conjunction with ergots or NSAIDs do not show a significant adjuvant effect on pain relief. Ergotamine tartrate was associated with the highest rate of adverse events, principally nausea, but concomitant administration of antinauseants or caffeine appear to improve its tolerability. CONCLUSIONS: Several self-administered drugs appear to be effective for the treatment of acute migraine. The inconclusive comparisons among classes of drugs and individual agents suggest that the choice among alternatives for the treatment of acute migraine may, for the present, depend more on side effects and contraindications than on data about efficacy.
catalogue key
9069577
technical details
Mode of access: Internet.
 
Includes bibliographical references.
Prepared for: Agency for Health Care Policy and Research, Department of Health and Human Services, U.S. Public Health Service, Rockville, Maryland. Contract No. 290-94-2025. Prepared by: Center for Clinical Health Policy Research, Duke University.

  link to old catalogue

Report a problem